Treatment simplification in HIV-infected adults as a strategy to prevent toxicity, improve adherence, quality of life and decrease healthcare costs

References

• Panel on Antiretroviral Guidelines for Adults and AdolescentsGuidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescentsDepartment of Health and Human Services11020111166 Available from: http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf. Accessed 2011 Feb 14.
   Google Scholar
• McKinnonJEMellorsJWSwindellsSSimplification strategies to reduce antiretroviral drug exposure: progress and prospectsAntivir Ther200914111219320232
   PubMed Web of Science ®Google Scholar
• World Health OrganizationAntiretroviral Therapy For HIV Infection Adults And Adolescents: Recommendations for a public health approach 2010 revision. Available from: http://whqlibdoc.who.int/publications/2010/9789241599764_eng.pdf.
   Google Scholar
• HenryKBrundageRWellerDAkinseteOShetAComparison of generic zidovudine plus lamivudine (Cipla, Duovir) and the GlaxoSmithKline brand (Combivir) tabletsJ Acquir Immune Defic Syndr200435553715021319
   PubMed Web of Science ®Google Scholar
• VezinaHHenryKRavindranGDA randomized crossover study to determine bioequivalence of generic and brand name nevirapine, zidovudine, and lamivudine in HIV-negative women in IndiaJ Acquir Immune Defic Syndr200641213113616394842
   PubMed Web of Science ®Google Scholar
• ParientiJJBangsbergDRVerdonRGardnerEMBetter adherence with once-daily antiretroviral regimens: a meta-analysisClin Infect Dis200948448448819140758
   PubMed Web of Science ®Google Scholar
• MaitlandDJacksonAOsorioJSwitch Study TeamSwitching from twice-daily abacavir and lamivudine to the once-daily fixed-dose combination tablet of abacavir and lamivudine improves patient adherence and satisfaction with therapyHIV Med20089866767218631255
   PubMed Web of Science ®Google Scholar
• WrightDRodriguezAGodofskyEEfficacy and safety of 48 weeks of enfuvirtide 180 mg once-daily dosing versus 90 mg twice-daily dosing in HIV-infected patientsHIV Clin Trials200892738218474492
   PubMed Web of Science ®Google Scholar
• BoyleBAJayaweeraDWittMDRandomization to once-daily stavudine extended release/lamivudine/efavirenz versus a more frequent regimen improves adherence while maintaining viral suppressionHIV Clin Trials20089316417618547903
   PubMed Web of Science ®Google Scholar
• ZajdenvergRBadal-FaesenAndrade-VillanuevaJLopinavir/ritonavir (LPV/r) tablets administered once-(QD) or twice-daily (BID) with NRTIs in antiretroviral-experienced HIV-1 Infected subjects: results of a 48-week randomized trial (Study M06-802)5th IAS Conference on HIV pathogenesis, Treatment and PreventionCape Town, South Africa2009 Jul 19–22 Available from: http://www.ias2009.org/pag/Abstracts.aspx?AID=1249.
   Google Scholar
• BangsbergDRRaglandKMonkAA single tablet regimen is associated with higher adherence and viral suppression than multiple tablet regimens in HIV+ homeless and marginally housed peopleAIDS201024182835284021045636
   PubMed Web of Science ®Google Scholar
• DeJesusEPozniakAGallantJImprovement in Fasting Lipids but Minimal Recovery of Limb Fat Were Seen 96 Weeks After Switching from Lamivudine/Zidovudine Plus Efavirenz to Fixed-Dose Efavirenz/Emtricitabine/Tenofovir DF in HIV-Infected Patients49th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)September 12–15, 2009San Francisco, CA USA Poster# H-1572. Available from: http://www.hivandhepatitis.com/2009icr/icaac/pdfs/2_DeJesus.pdf. Accessed July 10, 2011.
   Google Scholar
• AiroldiMZaccarelliMBisiLOne-pill once-a-day HAART: a simplification strategy that improves adherence and quality of life of HIV-infected subjectsPatient Prefer Adherence2010411512520517472
   PubMed Web of Science ®Google Scholar
• BaeJWGuyerWGrimmKAlticeFLMedication persistence in the treatment of HIV infection: a review of the literature and implications for future clinical care and researchAIDS201125327929021239892
   PubMed Web of Science ®Google Scholar
• WilligJHAbromsSWestfallAOIncreased regimen durability in the era of once-daily fixed-dose combination antiretroviral therapyAIDS200822151951196018784459
   PubMed Web of Science ®Google Scholar
• GardnerEMBurmanWJMaraviMEDavidsonAJSelective drug taking during combination antiretroviral therapy in an unselected clinic populationJ Acquir Immune Defic Syndr200540329430016249703
   PubMed Web of Science ®Google Scholar
• VoTTLedergerberBKeiserODurability and outcome of initial antiretroviral treatments received during 2000–2005 by patients in the Swiss HIV Cohort StudyJ Infect Dis2008197121685169418513155
   PubMed Web of Science ®Google Scholar
• DybulMChunTWYoderCShort-cycle structured intermittent treatment of chronic HIV infection with highly active antiretroviral therapy: effects on virologic, immunologic, and toxicity parametersProc Natl Acad Sci U S A20019826151611516611734634
   PubMed Web of Science ®Google Scholar
• DybulMNies-KraskeEDewarRA proof-of-concept study of short-cycle intermittent antiretroviral therapy with a once-daily regimen of didanosine, lamivudine, and efavirenz for the treatment of chronic HIV infectionJ Infect Dis2004189111974198215143462
   PubMed Web of Science ®Google Scholar
• CohenCJColsonAESheble-HallAGMcLaughlinKAMorseGDPilot study of a novel short-cycle antiretroviral treatment interruption strategy: 48-week results of the five-days-on, two-days-off (FOTO) studyHIV Clin Trials200781192317434845
   PubMed Web of Science ®Google Scholar
• CohenCColsonAPieroneG5th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention The FOTO study: the 48 week extension to assess durability of the strategy of taking efavirenz, tenofovir and emtricitabine Five days On, Two days Off (FOTO) each week in virologically suppressed patients,Cape Town, South Africa2009 Jul 19–22 Ab#MOPEB063. Available from http://www.ias2009.org/pag/Abstracts.aspx?AID=3046.
   Google Scholar
• DanelCMohRMingaATrivacan ANRS 1269 trial groupCD4-guided structured antiretroviral treatment interruption strategy in HIV-infected adults in west Africa (Trivacan ANRS 1269 trial): a randomised trialLancet200636795271981198916782488
   PubMed Web of Science ®Google Scholar
• AnanworanichJGayet-AgeronALe BrazMStaccato Study GroupSwiss HIV Cohort Study. CD4-guided scheduled treatment interruptions compared with continuous therapy for patients infected with HIV-1: results of the Staccato randomised trialLancet2006368953445946516890832
   PubMed Web of Science ®Google Scholar
• El-SadrWMLundgrenJDNeatonJDStrategies for Management of Antiretroviral Therapy (SMART) Study Group. CD4+ count-guided interruption of antiretroviral treatmentN Engl J Med2006355222283229617135583
   PubMed Web of Science ®Google Scholar
• El-SadrWMGrundBNeuhausJRisk for opportunistic disease and death after reinitiating continuous antiretroviral therapy in patients with HIV previously receiving episodic therapy: a randomized trialAnn Intern Med2008149528929918765698
   PubMed Web of Science ®Google Scholar
• LundgrenJDBabikerAEl-SadrWInferior clinical outcome of the CD4+ cell count-guided antiretroviral treatment interruption strategy in the SMART study: role of CD4+ Cell counts and HIV RNA levels during follow-up. Strategies for Management of Antiretroviral Therapy (SMART) Study GroupJ Infect Dis200819781145115518476293
   PubMed Web of Science ®Google Scholar
• EmerySNeuhausJAPhillipsANMajor clinical outcomes in antiretroviral therapy (ART)-naive participants and in those not receiving ART at baseline in the SMART studyJ Infect Dis200819781133114418476292
   PubMed Web of Science ®Google Scholar
• KaufmannGRElziLWeberRInterruptions of cART limits CD4 T-cell recovery and increases the risk for opportunistic complications and deathAIDS201125444145121206265
   PubMed Web of Science ®Google Scholar
• HavlirDVMarschnerIAHirschMSMaintenance antiretroviral therapies in HIV-infected subjects with undetectable plasma HIV RNA after triple-drug therapyN Engl J Med199833918126112689791141
   PubMed Web of Science ®Google Scholar
• PialouxGRaffiFBrun-VezinetFTrilège (Agence Nationale de Recherches sur le SIDA 072) Study TeamA randomized trial of three maintenance regimens given after three months of induction therapy with zidovudine, lamivudine, and indinavir in previously untreated HIV-1-infected patientsN Engl J Med199833918126912769791142
   PubMed Web of Science ®Google Scholar
• OpravilMHirschelBLazzarinAA randomized trial of simplified maintenance therapy with abacavir, lamivudine, and zidovudine in human immunodeficiency virus infectionJ Infect Dis200218591251126012001042
   PubMed Web of Science ®Google Scholar
• KatlamaCFenskeSGazzardBTRIZAL study: switching from successful HAART to Trizivir (abacavir-lamivudine-zidovudine combination tablet): 48 weeks efficacy, safety and adherence resultsHIV Med200342798612702127
   PubMedGoogle Scholar
• MarkowitzMHill-ZabalaCLangJInduction with abacavir/lamivudine/zidovudine plus efavirenz for 48 weeks followed by 48-week maintenance with abacavir/lamivudine/zidovudine alone in antiretroviral-naive HIV-1-infected patientsJ Acquir Immune Defic Syndr200539325726415980684
   PubMed Web of Science ®Google Scholar
• MallolasJPichJPenarandaMInduction therapy with trizivir plus efavirenz or lopinavir/ritonavir followed by trizivir alone in naive HIV-1-infected adultsAIDS200822337738418195564
   PubMed Web of Science ®Google Scholar
• OpravilMBaumannDChaveJPLong-term efficacy after switch from protease inhibitor-containing highly active antiretroviral therapy to abacavir, lamivudine, and zidovudineAIDS200418162213221515577660
   PubMed Web of Science ®Google Scholar
• DelfraissyJFFlandrePDelaugerreCLopinavir/ritonavir monotherapy or plus zidovudine and lamivudine in antiretroviral-naive HIV-infected patientsAIDS200822338539318195565
   PubMed Web of Science ®Google Scholar
• WilkinTJMcKinnonJEDiRienzoAGRegimen simplification to atazanavir-ritonavir alone as maintenance antiretroviral therapy: final 48-week clinical and virologic outcomesJ Infect Dis2009199686687119191590
   PubMed Web of Science ®Google Scholar
• BiermanWFvan AgtmaelMANijhuisMDannerSABoucherCAHIV monotherapy with ritonavir-boosted protease inhibitors: a systematic reviewAIDS200923327929119114854
   PubMed Web of Science ®Google Scholar
• ArribasJRPulidoFDelgadoRLopinavir/ritonavir as single-drug therapy for maintenance of HIV-1 viral suppression: 48-week results of a randomized, controlled, open-label, proof-of-concept pilot clinical trial (OK Study)J Acquir Immune Defic Syndr200540328028716249701
   PubMed Web of Science ®Google Scholar
• ArribasJRDelgadoRArranzAOK04 Study GroupLopinavir-ritonavir monotherapy versus lopinavir-ritonavir and 2 nucleosides for maintenance therapy of HIV: 96-week analysisJ Acquir Immune Defic Syndr200951214715219349870
   PubMed Web of Science ®Google Scholar
• SwindellsSDiRienzoAGWilkinTRegimen simplification to atazanavir-ritonavir alone as maintenance antiretroviral therapy after sustained virologic suppressionJAMA2006296780681416905786
   PubMed Web of Science ®Google Scholar
• KarlstromOJosephsonFSonnerborgAEarly virologic rebound in a pilot trial of ritonavir-boosted atazanavir as maintenance monotherapyJ Acquir Immune Defic Syndr200744441742217159658
   PubMed Web of Science ®Google Scholar
• ArribasJRHorbanAGerstoftJThe MONET trial: darunavir/ritonavir with or without nucleoside analogues, for patients with HIV RNA below 50 copies/mlAIDS201024222323020010070
   PubMed Web of Science ®Google Scholar
• KatlamaCValentinMAAlgarte-GeninGEfficacy of darunavir/ritonavir as single-drug maintenance therapy in patients with HIV-1 viral suppression: a randomized open-label noninferiority trial, MONOI-ANRS 136AIDS201024152365237420802297
   PubMed Web of Science ®Google Scholar
• GallantJEDeJesusEArribasJRStudy 934 GroupTenofovir DF, emtricitabine, and efavirenz vs zidovudine, lamivudine, and efavirenz for HIVN Engl J Med2006354325126016421366
   PubMed Web of Science ®Google Scholar
• SaxPETierneyCCollierACAIDS Clinical Trials Group Study A5202 TeamAbacavir-lamivudine versus tenofovir-emtricitabine for initial HIV-1 therapyN Engl J Med2009361232230224019952143
   PubMed Web of Science ®Google Scholar
• MoyleGJSabinCACartledgeJRAVE (Randomized Abacavir versus Viread Evaluation) Group UKA randomized comparative trial of tenofovir DF or abacavir as replacement for a thymidine analogue in persons with lipoatrophyAIDS200620162043205017053350
   PubMed Web of Science ®Google Scholar
• FisherMMoyleGJShahmaneshMSWEET (Simplification With Easier Emtricitabine Tenofovir) Group UKA randomized comparative trial of continued zidovudine/lamivudine or replacement with tenofovir disoproxil fumarate/emtricitabine in efavirenz-treated HIV-1-infected individualsJ Acquir Immune Defic Syndr200951556256819561519
   PubMed Web of Science ®Google Scholar
• LaurentCBourgeoisAMpoudi-NgoléETolerability and effectiveness of first-line regimens combining nevirapine and lamivudine plus zidovudine or stavudine in CameroonAIDS Res Hum Retroviruses200824339339918327976
   PubMed Web of Science ®Google Scholar
• HawkinsCAchenbachCFrydaWAntiretroviral durability and tolerability in HIV-infected adults living in urban KenyaJ Acquir Immune Defic Syndr200745330431017414931
   PubMed Web of Science ®Google Scholar
• MehtaUMaartensGIs it safe to switch between efavirenz and nevirapine in the event of toxicity?Lancet Infect Dis200771173373817961859
   PubMed Web of Science ®Google Scholar
• WatersLFisherMWinstonAA phase IV, double-blind, multicentre, randomized, placebo-controlled, pilot study to assess the feasibility of switching individuals receiving efavirenz with continuing central nervous system adverse events to etravirineAIDS2011251657121099666
   PubMed Web of Science ®Google Scholar
• MallolasJPodzamczerDMilinkovicAATAZIP Study GroupEfficacy and safety of switching from boosted lopinavir to boosted atazanavir in patients with virological suppression receiving a LPV/r-containing HAART: the ATAZIP studyJ Acquir Immune Defic Syndr2009511293619390327
   PubMed Web of Science ®Google Scholar
• MillsAMNelsonMJayaweeraDOnce-daily darunavir/ritonavir vs lopinavir/ritonavir in treatment-naive, HIV-1-infected patients: 96-week analysisAIDS200923131679168819487905
   PubMed Web of Science ®Google Scholar
• GatellJSalmon-CeronDLazzarinASWAN Study GroupEfficacy and safety of atazanavir-based highly active antiretroviral therapy in patients with virologic suppression switched from a stable, boosted or unboosted protease inhibitor treatment regimen: the SWAN Study (AI424-097) 48-week resultsClin Infect Dis200744111484149217479947
   PubMed Web of Science ®Google Scholar
• GrantPMPalmerSBendavidESwitch from enfuvirtide to raltegravir in virologically suppressed HIV-1 infected patients: effects on level of residual viremia and quality of lifeClin Virol2009464305308
   Web of Science ®Google Scholar
• De CastroNBraunJCharreauIEASIER ANRS 138 study groupSwitch from enfuvirtide to raltegravir in virologically suppressed multidrug-resistant HIV-1-infected patients: a randomized open-label trialClin Infect Dis20094981259126719757993
   PubMed Web of Science ®Google Scholar
• EronJJYoungBCooperDASwitch to a raltegravir-based regimen versus continuation of a lopinavir-ritonavir-based regimen in stable HIV-infected patients with suppressed viraemia (SWITCHMRK 1 and 2): two multicentre, double-blind, randomised controlled trialsLancet2010375971239640720074791
   PubMed Web of Science ®Google Scholar
• MartínezELarrousseMLlibreJMSPIRAL Study GroupSubstitution of raltegravir for ritonavir-boosted protease inhibitors in HIV-infected patients: the SPIRAL studyAIDS201024111697170720467288
   PubMed Web of Science ®Google Scholar
• VispoEBarreiroPMaidaISimplification from protease inhibitors to once- or twice-daily raltegravir: the ODIS trialHIV Clin Trials201011419720420974575
   PubMed Web of Science ®Google Scholar
• GardnerEMMaraviMERietmeijerCDavidsonAJBurmanWJThe association of adherence to antiretroviral therapy with healthcare utilization and costs for medical careAppl Health Econ Health Policy200862–314515519231907
   PubMedGoogle Scholar
• MandaliaSMandaliaRLoGNPMS-HHC Steering GroupRising population cost for treating people living with HIV in the UK, 1997–2013PLoS One2010512e1567721209893
   PubMed Web of Science ®Google Scholar
• The ADAP Watch42011 Available from: http://www.nastad.org/Docs/Public/InFocus/201148_ADAP%20Watch%20update%20-%204.8.11.pdf. Accessed on 2011 May 13.
   Google Scholar
• NachegaJBLeisegangRBishaiDAssociation of antiretroviral therapy adherence and health care costsAnn Intern Med20101521182520048268
   PubMed Web of Science ®Google Scholar
• GallantJEStaszewskiSPozniakEfficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naïve patients: a 3-year randomized trialJAMA2004292219120115249568
   PubMed Web of Science ®Google Scholar
• MilinkovicAMartinezELopezSThe impact of reducing stavudine dose versus switching to tenofovir on plasma lipids, body composition and mitochondrial function in HIV-infected patientsAntivir Ther200712340741517591031
   PubMed Web of Science ®Google Scholar
• Treatment Action CampaignTenofovir: an explanation of why we need TDF-dose combinations and the steps to bring them to the market in South Africa Available from: http://www.tac.org.za/community/node/2802; Accessed on 2011 May 13.
   Google Scholar
• Department of Health, Republic of South AfricaThe South African Antiretroviral Treatment Guidelines 2010 Available from: http://www.doh.gov.za/docs/factsheets/guidelines/art.pdf. Accessed on 2001 May 13.
   Google Scholar
• RosenSLongLFoxMSanneICost and cost-effectiveness of switching from stavudine to tenofovir in first-line antiretroviral therapy regimens in South AfricaJ Acquir Immune Defic Syndr200848333434418545151
   PubMed Web of Science ®Google Scholar